The DOI matches its Crossref record; 216 of the 216 references it cites were found in a registry or an index.
Androgen receptors in hormone-dependent and castration-resistant prostate cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R., Naishadham, D., & Jemal, A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21166 · Cited by 11,825
International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels
Catterall, W. A., Chandy, K. G., Clapham, D. E., Gutman, G. A., Hofmann, F., Harmar, A. J., Abernethy, D. R., & Spedding, M. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.4.5 · Cited by 7,126
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 2×
“Until recently, chemotherapy for treatment of CRPC was the only modality to demonstrate a survival benefit in a phase III clinical trial (Tannock et al., 2004; Berthold et al., 2008), supporting the FDA approval of docetaxel for patients with CRPC.”
BackgroundNormalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“Although the mechanism of action has not been elucidated, adding ADT may enhance radiation effects via increased tumor oxygenation (Zietman et al., 1997a; Zietman et al., 1997b; Kaminski et al., 2003; Jain, 2005; Stewart et al., 2011) and also by preventing dissemination of micro-metastatic disease.”
BackgroundAbiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407 · cited 2×
“…p b 0.001), time to PSA progression (10.2 vs 6.6 months, p b 0.001), PSA response rate (29% vs 6%, p b 0.001) and overall survival (14.8 vs 10.9 months, p b 0.001), compared to the placebo arm, providing a new option for this group of patients who are difficult to treat (De Bono et al., 2011).”
BackgroundInfluentialRecurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005) · Science · doi:10.1126/science.1117679 · Cited by 3,846
Integrative Genomic Profiling of Human Prostate Cancer
Taylor, B. S., Schultz, N., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B. S., Arora, V. K., Kaushik, P., Cerami, E., Reva, B., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.026 · Cited by 3,701
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Ryan, C. J., Smith, M. R., de Bono, J. S., Molina, A., Logothetis, C. J., de Souza, P., Fizazi, K., Mainwaring, P., Piulats, J. M., Ng, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209096 · Cited by 2,796
Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement
Moyer, V. A., & on behalf of the U.S. Preventive Services Task Force* (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-2-201207170-00459 · Cited by 2,522
The development of androgen-independent prostate cancer.
Feldman, B. J., & Feldman, D. (2001) · Nature reviews. Cancer · doi:10.1038/35094009 · Cited by 2,326
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., et al. (2009) · Science · doi:10.1126/science.1168175 · Cited by 2,292 · cited 4×
“Instead, 10 μM MDV3100 is required (Tran et al., 2009).”
BackgroundInfluentialMolecular determinants of resistance to antiandrogen therapy
Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278
Ornitz, D. M., & Itoh, N. (2001) · Genome biology · doi:10.1186/gb-2001-2-3-reviews3005 · Cited by 2,272
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
Minucci, S., & Pelicci, P. G. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1779 · Cited by 2,200
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer
Barbieri, C. E., Baca, S. C., Lawrence, M. S., Demichelis, F., Blattner, M., Theurillat, J.-P., White, T. A., Stojanov, P., Van Allen, E., Stransky, N., et al. (2012) · Nature Genetics · doi:10.1038/ng.2279 · Cited by 1,558
Bolla, M., Gonzalez, D., Warde, P., Dubois, J. B., Mirimanoff, R.-O., Storme, G., Bernier, J., Kuten, A., Sternberg, C., Gil, T., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707313370502 · Cited by 1,548
In vivo amplification of the androgen receptor gene and progression of human prostate cancer
Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinänen, R., Palmberg, C., Palotie, A., Tammela, T., Isola, J., & Kallioniemi, O.-P. (1995) · Nature Genetics · doi:10.1038/ng0495-401 · Cited by 1,484 · cited 2×
“tion leading to AR protein over-expression (Visakorpi et al., 1995).”
BackgroundMontgomery, R. B., Mostaghel, E. A., Vessella, R., Hess, D. L., Kalhorn, T. F., Higano, C. S., True, L. D., & Nelson, P. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0249 · Cited by 1,419
Carver, B. S., Chapinski, C., Wongvipat, J., Hieronymus, H., Chen, Y., Chandarlapaty, S., Arora, V. K., Le, C., Koutcher, J., Scher, H., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.008 · Cited by 1,198
Berthold, D. R., Pond, G. R., Soban, F., de Wit, R., Eisenberger, M., & Tannock, I. F. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.4008 · Cited by 1,145
Wang, S., Gao, J., Lei, Q., Rozengurt, N., Pritchard, C., Jiao, J., Thomas, G. V., Li, G., Roy-Burman, P., Nelson, P. S., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00215-0 · Cited by 1,109 · cited 1×
“In mouse models, homozygous deletion of PTEN is sufficient to induce tumors that metastasize (Wang et al., 2003).”
BackgroundHu, R., Dunn, T. A., Wei, S., Isharwal, S., Veltri, R. W., Humphreys, E., Han, M., Partin, A. W., Vessella, R. L., Isaacs, W. B., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2764 · Cited by 1,077
Scher, H. I., & Sawyers, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4777 · Cited by 1,025
Craft, N., Shostak, Y., Carey, M., & Sawyers, C. L. (1999) · Nature Medicine · doi:10.1038/6495 · Cited by 980
Veldscholte, J., Ris-Stalpers, C., Kuiper, G. G. J. M., Jenster, G., Berrevoets, C., Claassen, E., van Rooij, H. C. J., Trapman, J., Brinkmann, A. O., & Mulder, E. (1990) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(05)80067-1 · Cited by 950
Androgen Receptor (AR) Coregulators: An Overview
Heinlein, C. A., & Chang, C. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.2.0460 · Cited by 943
Molecular Biology of the Androgen Receptor
Gelmann, E. P. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.018 · Cited by 942
Čulig, Z., Hobisch, A., Cronauer, M. V., Radmayr, C., Trapman, J., Hittmair, A., Bartsch, G., & Klocker, H. (1994) · PubMed · Cited by 938
Attard, G., Reid, A. H. M., Yap, T. A., Raynaud, F., Dowsett, M., Settatree, S., Barrett, M., Parker, C., Martins, V., Folkerd, E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9749 · Cited by 903
Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer
Wang, Q., Li, W., Zhang, Y., Yuan, X., Xu, K., Yu, J., Chen, Z., Beroukhim, R., Wang, H., Lupien, M., et al. (2009) · Cell · doi:10.1016/j.cell.2009.04.056 · Cited by 902
Messing, E. M., Manola, J., Yao, J., Kiernan, M., Crawford, D., Wilding, G., di'SantAgnese, P. A., & Trump, D. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70700-8 · Cited by 893
Guo, Z., Yang, X., Sun, F., Jiang, R., Linn, D. E., Chen, H., Chen, H., Kong, X., Melamed, J., Tepper, C. G., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3795 · Cited by 880
The CAG repeat within the androgen receptor gene and its relationship to prostate cancer
Giovannucci, E., Stampfer, M. J., Krithivas, K., Brown, M., Brufsky, A., Talcott, J., Hennekens, C. H., & Kantoff, P. W. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.7.3320 · Cited by 873
Yu, J., Yu, J., Mani, R.-S., Cao, Q., Brenner, C. J., Cao, X., Wang, X., Wu, L., Li, J., Hu, M., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.018 · Cited by 850
Dehm, S. M., Schmidt, L. J., Heemers, H. V., Vessella, R. L., & Tindall, D. J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0594 · Cited by 834
Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials
(2000) · The Lancet · doi:10.1016/s0140-6736(00)02163-2 · Cited by 819
Transforming growth factor-beta: recent progress and new challenges.
Sporn, M. B., & Roberts, A. B. (1992) · The Journal of cell biology · doi:10.1083/jcb.119.5.1017 · Cited by 769
Heemers, H. V., & Tindall, D. J. (2007) · Endocrine Reviews · doi:10.1210/er.2007-0019 · Cited by 753
Sun, S., Sprenger, C. C. T., Vessella, R. L., Haugk, K., Soriano, K., Mostaghel, E. A., Page, S. T., Coleman, I. M., Nguyen, H. M., Sun, H., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41824 · Cited by 748
Locke, J. A., Guns, E. S., Lubik, A. A., Adomat, H. H., Hendy, S. C., Wood, C. A., Ettinger, S. L., Gleave, M. E., & Nelson, C. C. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5997 · Cited by 747 · cited 1×
“Progesterone is converted through a series of steps to 5α-androstane-3-α,17β-diol, which then is converted directly to DHT (Locke et al., 2008).”
BackgroundA luminal epithelial stem cell that is a cell of origin for prostate cancer
Wang, X., Julio, M. K.-D., Economides, K. D., Walker, D., Yu, H., Halili, M. V., Hu, Y.-P., Price, S. M., Abate-Shen, C., & Shen, M. M. (2009) · Nature · doi:10.1038/nature08361 · Cited by 734
Radiotherapy and Short-Term Androgen Deprivation for Localized Prostate Cancer
Jones, C. U., Hunt, D., McGowan, D. G., Amin, M. B., Chetner, M. P., Bruner, D. W., Leibenhaut, M. H., Husain, S. M., Rotman, M., Souhami, L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1012348 · Cited by 696
Androgen Suppression and Radiation vs Radiation Alone for Prostate Cancer: A Randomized Trial
D’Amico, A. V., Chen, M.-H., Renshaw, A. A., Loffredo, M., & Kantoff, P. W. (2008) · JAMA · doi:10.1001/jama.299.3.289 · Cited by 690
Role of the TMPRSS2-ERG Gene Fusion in Prostate Cancer
Tomlins, S. A., Laxman, B., Varambally, S., Cao, X., Yu, J., Helgeson, B. E., Cao, Q., Prensner, J. R., Rubin, M. A., Shah, R. B., et al. (2008) · Neoplasia · doi:10.1593/neo.07822 · Cited by 690
Hanks, G. E., Pajak, T. F., Porter, A., Grignon, D., Brereton, H., Venkatesan, V., Horwitz, E. M., Lawton, C., Rosenthal, S. A., Sandler, H. M., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.023 · Cited by 689
Wang, Q., Li, W., Liu, X. S., Carroll, J. S., Jänne, O. A., Keeton, E. K., Chinnaiyan, A. M., Pienta, K. J., & Brown, M. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.041 · Cited by 687
The Androgen Axis in Recurrent Prostate Cancer
Mohler, J. L., Gregory, C. W., Ford, O. H., Kim, D., Weaver, C. M., Petrusz, P., Wilson, E. M., & French, F. S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1146-03 · Cited by 675
The Role of Increasing Detection in the Rising Incidence of Prostate Cancer
Potosky, A. L. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03520310046028 · Cited by 674
ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
Clegg, N. J., Wongvipat, J., Joseph, J. D., Tran, C., Ouk, S., Dilhas, A., Chen, Y., Grillot, K., Bischoff, E. D., Cai, L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3948 · Cited by 662
Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate
Carver, B. S., Tran, J., Gopalan, A., Chen, Z., Shaikh, S., Carracedo, A., Alimonti, A., Nardella, C., Varmeh, S., Scardino, P. T., et al. (2009) · Nature Genetics · doi:10.1038/ng.370 · Cited by 659
Roach, M., Bae, K., Speight, J., Wolkov, H. B., Rubin, P., Lee, R. J., Lawton, C., Valicenti, R., Grignon, D., & Pilepich, M. V. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9881 · Cited by 649
Watson, P. A., Chen, Y. F., Balbas, M. D., Wongvipat, J., Socci, N. D., Viale, A., Kim, K., & Sawyers, C. L. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012443107 · Cited by 639
The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis
Massie, C. E., Lynch, A., Ramos‐Montoya, A., Boren, J., Stark, R., Fazli, L., Warren, A., Scott, H., Madhu, B., Sharma, N., et al. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.158 · Cited by 624 · cited 2×
“25 pmol/g) was sufficiently high to cause some AR activation (Massie et al., 2011).”
BackgroundInfluentialYeh, S., & Chang, C. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.11.5517 · Cited by 623
Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.
Taplin, M., Bubley, G. J., Ko, Y., Small, E. J., Upton, M. P., Rajeshkumar, B. R., & Balk, S. P. (1999) · PubMed · Cited by 596
Bubendorf, L., Kononen, J., Koivisto, P. A., Schraml, P., Moch, H., Gasser, T. C., Willi, N., Mihatsch, M. J., Sauter, G., & Kallioniemi, O. (1999) · PubMed · Cited by 594
Lin, C., Yang, L., Tanasa, B., Hutt, K., Ju, B.-G., Ohgi, K. A., Zhang, J., Rose, D. W., Fu, X.-D., Glass, C. K., et al. (2009) · Cell · doi:10.1016/j.cell.2009.11.030 · Cited by 576
The Roles of Androgen Receptors and Androgen-Binding Proteins in Nongenomic Androgen Actions
Heinlein, C. A., & Chang, C. (2002) · Molecular Endocrinology · doi:10.1210/me.2002-0070 · Cited by 568 · cited 2×
“For some coregulators, increased protein expression is correlated with PCa progression (Heinlein & Chang, 2002a; Chen et al., 2008).”
BackgroundAndrogen insensitivity syndrome
Hughes, I. A., Davies, J. D., Bunch, T. I., Pasterski, V., Mastroyannopoulou, K., & MacDougall, J. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60071-3 · Cited by 553
The LNCaP cell line--a new model for studies on human prostatic carcinoma.
Horoszewicz, J. S., Leong, S. S., Chu, T. M., Wajsman, Z., Friedman, M., Papsidero, L. D., Kim, U., Chai, L. S., Kakati, S., Arya, S. K., et al. (1980) · PubMed · Cited by 544
Mostaghel, E. A., Page, S. T., Lin, D. W., Fazli, L., Coleman, I. M., True, L. D., Knudsen, B., Hess, D. L., Nelson, C. C., Matsumoto, A. M., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3332 · Cited by 529
The androgen receptor gene mutations database: 2012 update
Gottlieb, B., Beitel, L. K., Nadarajah, A., Paliouras, M., & Trifiro, M. (2012) · Human Mutation · doi:10.1002/humu.22046 · Cited by 512
Andersen, R. J., Mawji, N. R., Wang, J., Wang, G., Haile, S., Myung, J.-K., Watt, K., Tam, T., Yang, Y. C., Bañuelos, C. A., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.04.027 · Cited by 503
(2001) · PubMed · Cited by 500
Intermittent Androgen Suppression for Rising PSA Level after Radiotherapy
Crook, J. M., O'Callaghan, C. J., Duncan, G., Dearnaley, D. P., Higano, C. S., Horwitz, E. M., Frymire, E., Malone, S., Chin, J., Nabid, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1201546 · Cited by 499
Hörnberg, E., Ylitalo, E. B., Crnalic, S., Antti, H., Stattin, P., Widmark, A., Bergh, A., & Wikström, P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019059 · Cited by 498
Sack, J. S., Kish, K. F., Wang, C., Attar, R. M., Kiefer, S. E., An, Y., Wu, G. Y., Scheffler, J. E., Salvati, M. E., Krystek, S. R., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081565498 · Cited by 491
Lorenzo, G. D., Tortora, G., D’Armiento, F. P., Rosa, G. D., Staibano, S., Riccardo Autorino, B., D’Armiento, M., Laurentiis, M. D., Placido, S. D., Catalano, G., et al. (2002) · PubMed · Cited by 474
Beltran, H., Yelensky, R., Frampton, G. M., Park, K., Downing, S. R., MacDonald, T. Y., Jarosz, M., Lipson, D., Tagawa, S. T., Nanus, D. M., et al. (2013) · European Urology · doi:10.1016/j.eururo.2012.08.053 · Cited by 454
Wang, Q., Carroll, J. S., & Brown, M. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.07.018 · Cited by 450
Denham, J. W., Steigler, A., Lamb, D. S., Joseph, D., Turner, S., Matthews, J., Atkinson, C., North, J., Christie, D., Spry, N. A., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70063-8 · Cited by 450
Hobisch, A., Eder, I. E., Putz, T., Horninger, W., Bartsch, G. C., Klocker, H., & Čulig, Z. (1998) · PubMed · Cited by 437
Cai, C., Chen, S., Ng, P., Bubley, G. J., Nelson, P. S., Mostaghel, E. A., Marck, B., Matsumoto, A. M., Simon, N. I., Wang, H., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0532 · Cited by 433
Darshan, M. S., Loftus, M. S., Thadani-Mulero, M., Levy, B. P., Escuin, D., Zhou, X. K., Gjyrezi, A., Chanel-Vos, C., Shen, R., Tagawa, S. T., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1417 · Cited by 432
Activation of the human androgen receptor through a protein kinase A signaling pathway.
Nazareth, L. V., & Weigel, N. L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.33.19900 · Cited by 429
Self-citationLu, N. Z., Wardell, S. E., Burnstein, K. L., Defranco, D., Fuller, P. J., Giguere, V., Hochberg, R. B., McKay, L., Renoir, J.-M., Weigel, N. L., et al. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.4.9 · Cited by 426
Self-citationThe AF1 and AF2 Domains of the Androgen Receptor Interact with Distinct Regions of SRC1
Bevan, C. L., Hoare, S., Claessens, F., Heery, D. M., & Parker, M. G. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.12.8383 · Cited by 425
Structural basis for antagonism and resistance of bicalutamide in prostate cancer
Bohl, C. E., Gao, W., Miller, D. D., Bell, C. E., & Dalton, J. T. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500381102 · Cited by 421
Roy, A. K., Lavrovsky, Y., Song, C. S., Chen, S., Jung, M. H., Velu, N. K., Bi, B. Y., & Chatterjee, B. (1998) · Vitamins & Hormones · doi:10.1016/s0083-6729(08)60938-3 · Cited by 411
Wang, J., Cai, Y., Ren, C., & Ittmann, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1966 · Cited by 404
Zegarra-Moro, O. L., Schmidt, L. J., Huang, H., & Tindall, D. J. (2002) · PubMed · Cited by 399
Overcoming mutation-based resistance to antiandrogens with rational drug design
Balbas, M. D., Evans, M. J., Hosfield, D. J., Wongvipat, J., Arora, V. K., Watson, P. A., Chen, Y., Greene, G. L., Shen, Y., & Sawyers, C. L. (2013) · eLife · doi:10.7554/elife.00499 · Cited by 397
Her-2-neu Expression and Progression Toward Androgen Independence in Human Prostate Cancer
Signoretti, S. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.23.1918 · Cited by 397
Induced Chromosomal Proximity and Gene Fusions in Prostate Cancer
Mani, R.-S., Tomlins, S. A., Callahan, K., Ghosh, A., Nyati, M. K., Varambally, S., Palanisamy, N., & Chinnaiyan, A. M. (2009) · Science · doi:10.1126/science.1178124 · Cited by 391
Targeting the androgen receptor pathway in prostate cancer
Chen, Y., Sawyers, C. L., & Scher, H. I. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.07.005 · Cited by 389
O'Donnell, A., Judson, I., Dowsett, M., Raynaud, F., Dearnaley, D., Mason, M., Harland, S., Robbins, A., Halbert, G., Nutley, B., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601879 · Cited by 382
Alternatively spliced androgen receptor variants
Dehm, S. M., & Tindall, D. J. (2011) · Endocrine-Related Cancer · doi:10.1530/erc-11-0141 · Cited by 380
Lawton, C. A., Winter, K., Murray, K., Machtay, M., Mesic, J. B., Hanks, G. E., Coughlin, C. T., & Pilepich, M. V. (2001) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(00)01516-9 · Cited by 374
Regulation of androgen receptor activity by tyrosine phosphorylation.
Guo, Z., Dai, B., Jiang, T., Xu, K., Xie, Y., Kim, O., Nesheiwat, I., Kong, X., Melamed, J., Handratta, V. D., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.021 · Cited by 364 · cited 1×
“Src kinase, which is also downstream of growth factor receptors, has been implicated in AR crosstalk through its ability to phosphorylate AR and increase transcriptional activity (Guo et al., 2006; Kraus et al., 2006; Migliaccio et al., 2007).”
BackgroundTubulin-Targeting Chemotherapy Impairs Androgen Receptor Activity in Prostate Cancer
Zhu, M.-L., Horbinski, C. M., Garzotto, M., Qian, D. Z., Beer, T. M., & Kyprianou, N. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0585 · Cited by 352
Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer
Chang, K.-H., Li, R., Papari-Zareei, M., Watumull, L., Zhao, Y. D., Auchus, R. J., & Sharifi, N. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1107898108 · Cited by 346
Mellinghoff, I. K., Vivanco, I., Kwon, A., Tran, C., Wongvipat, J., & Sawyers, C. L. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.031 · Cited by 344 · cited 1×
“Some advanced CRPC samples are characterized by HER2 receptor tyrosine kinase over-expression that increases AR activity and stability; inhibition of HER2 causes growth suppression (Craft et al., 1999; Signoretti et al., 2000; Mellinghoff et al., 2004).”
BackgroundStructures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001
DeVore, N. M., & Scott, E. E. (2012) · Nature · doi:10.1038/nature10743 · Cited by 341
Drug resistance in metastatic castration-resistant prostate cancer
Seruga, B., Ocana, A., & Tannock, I. F. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.136 · Cited by 336
The reactive stroma microenvironment and prostate cancer progression
Barron, D. A., & Rowley, D. R. (2012) · Endocrine-Related Cancer · doi:10.1530/erc-12-0085 · Cited by 329
Role of stromal-epithelial interactions in hormonal responses
Cunha, G. R., Cooke, P. S., & Kurita, T. (2004) · Archives of Histology and Cytology · doi:10.1679/aohc.67.417 · Cited by 316
The androgen receptor gene mutations database (ARDB): 2004 update
Gottlieb, B., Beitel, L. K., Wu, J. H., & Trifiro, M. (2004) · Human Mutation · doi:10.1002/humu.20044 · Cited by 311
Ueda, T., Mawji, N. R., Bruchovsky, N., & Sadar, M. D. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203313200 · Cited by 311 · cited 2×
“For instance, treatment of PCa cells in androgen-depleted medium with pharmacological activators of the Protein Kinase A pathway, growth factors, or IL-6 is sufficient to activate AR in vitro (Nazareth & Weigel, 1996; Ueda et al., 2002).”
BackgroundUpdate on Hsp90 Inhibitors in Clinical Trial
Kim, Y., Alarcon, S., Lee, S., Lee, M.-J., Giaccone, G., Neckers, L., & Trepel, J. (2009) · Current Topics in Medicinal Chemistry · doi:10.2174/156802609789895728 · Cited by 311
Prooxidant-Antioxidant Shift Induced by Androgen Treatment of Human Prostate Carcinoma Cells
Ripple, M. O., Wilding, G., Henry, W. F., & Rago, R. P. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.1.40 · Cited by 309
Wang, Z. A., Mitrofanova, A., Bergren, S. K., Abate-Shen, C., Cardiff, R. D., Califano, A., & Shen, M. M. (2013) · Nature Cell Biology · doi:10.1038/ncb2697 · Cited by 304
Androgen receptor and growth factor signaling cross-talk in prostate cancer cells.
Zhu, M.-L., & Kyprianou, N. (2008) · Endocrine Related Cancer · doi:10.1677/erc-08-0084 · Cited by 286 · cited 1×
“AR cross talks with numerous growth factors including transforming growth factor β (TGFβ), vascular endothelial growth factor (VEGF), insulin-like growth factor (IGF), fibroblast growth factor (FGF), and epidermal growth factor (EGF) (Culig et al., 1994; Zhu & Kyprianou, 2008).”
BackgroundRequirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells
Qiu, Y., Ravi, L., & Kung, H.-J. (1998) · Nature · doi:10.1038/30012 · Cited by 280
Yoshimoto, M., Joshua, A. M., Cunha, I. W., Coudry, R. A., Fonseca, F. P., Ludkovski, O., Zielenska, M., Soares, F. A., & Squire, J. A. (2008) · Modern Pathology · doi:10.1038/modpathol.2008.96 · Cited by 279
Basal epithelial stem cells are efficient targets for prostate cancer initiation
Lawson, D. A., Zong, Y., Memarzadeh, S., Xin, L., Huang, J., & Witte, O. N. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0913873107 · Cited by 275
Gregory, C. W., Hamil, K. G., Kim, D., Hall, S. H., Pretlow, T. G., Mohler, J. L., & French, F. S. (1998) · PubMed · Cited by 275
Mahajan, N. P., Liu, Y., Majumder, S., Warren, M. R., Parker, C. E., Mohler, J. L., Earp, H. S., & Whang, Y. E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700420104 · Cited by 274
Beilin, J., Ball, E., Favaloro, J., & Zajac, J. (2000) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0250085 · Cited by 265
Samson, D. J., Seidenfeld, J., Schmitt, B., Hasselblad, V., Albertsen, P. C., Bennett, C. L., Wilt, T. J., & Aronson, N. (2002) · Cancer · doi:10.1002/cncr.10647 · Cited by 259
Richards, J., Lim, A. C., Hay, C. W., Taylor, A. E., Wingate, A., Nowakowska, K., Pezaro, C., Carreira, S., Goodall, J., Arlt, W., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3980 · Cited by 259
Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer
Kumar, S., Shelley, M., Harrison, C., Coles, B., Wilt, T. J., & Mason, M. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006019.pub2 · Cited by 257
Multiple Signal Input and Output Domains of the 160-Kilodalton Nuclear Receptor Coactivator Proteins
Ma, H., Hong, H., Huang, S.-M., Irvine, R. A., Webb, P., Kushner, P. J., Coetzee, G. A., & Stallcup, M. R. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.9.6164 · Cited by 256
Sun, C., Dobi, A., Mohamed, A., Li, H., Thangapazham, R. L., Furusato, B., Shaheduzzaman, S., Tan, S.-H., Vaidyanathan, G., Whitman, E., et al. (2008) · Oncogene · doi:10.1038/onc.2008.183 · Cited by 253
on behalf of the Transatlantic Prostate Group, Reid, A. H. M., Attard, G., Ambroisine, L., Fisher, G., Kovacs, G., Brewer, D., Clark, J., Flohr, P., Edwards, S., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605554 · Cited by 250
SRC-3 Is Required for Prostate Cancer Cell Proliferation and Survival
Zhou, H.-J., Yan, J., Luo, W., Ayala, G., Lin, S.-H., Erdem, H., Ittmann, M., Tsai, S. Y., & Tsai, M.-J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4076 · Cited by 246
Geng, C., He, B., Xu, L., Barbieri, C. E., Eedunuri, V. K., Chew, S. A., Zimmermann, M., Bond, R., Shou, J., Li, C., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1304502110 · Cited by 246
Androgen Receptor Variants Occur Frequently in Castration Resistant Prostate Cancer Metastases
Zhang, X., Morrissey, C., Sun, S., Ketchandji, M., Nelson, P. S., True, L. D., Vakar-Lopez, F., Vessella, R. L., & Plymate, S. R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027970 · Cited by 240
Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer
Scher, H. I., Buchanan, G., Gerald, W., Butler, L. M., & Tilley, W. D. (2004) · Endocrine-Related Cancer · doi:10.1677/erc.1.00525 · Cited by 240
Waltering, K. K., Helenius, M. A., Sahu, B., Manni, V., Linja, M. J., Jänne, O. A., & Visakorpi, T. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0919 · Cited by 228
Dillard, P. R., Lin, M.-F., & Khan, S. A. (2008) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.08.013 · Cited by 225
Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis☆
Schally, A. V. (1999) · Peptides · doi:10.1016/s0196-9781(99)00130-8 · Cited by 220
Chan, S. C., Li, Y., & Dehm, S. M. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.352930 · Cited by 218
Steroidogenic Acute Regulatory Protein (StAR) Is A Sterol Transfer Protein
Kallen, C. B., Billheimer, J. T., Summers, S. A., Stayrook, S. E., Lewis, M., & Strauss, J. F. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.41.26285 · Cited by 217
Suzuki, H., Akakura, K., Komiya, A., Aida, S., Akimoto, S., & Shimazaki, J. (1996) · The Prostate · doi:10.1002/1097-0045(199609)29:3<153::aid-pros2990290303>3.0.co;2-5 · Cited by 208
Hu, R., Isaacs, W. B., & Luo, J. (2011) · The Prostate · doi:10.1002/pros.21382 · Cited by 207
Kemppainen, J. A. (1999) · Molecular Endocrinology · doi:10.1210/me.13.3.440 · Cited by 207
Zong, Y., Xin, L., Goldstein, A. S., Lawson, D. A., Teitell, M. A., & Witte, O. N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905931106 · Cited by 203 · cited 3×
“Several groups have reported that artificial expression of the protein inmouse prostate is insufficient to produce tumors (Carver et al., 2009; Zong et al., 2009).”
BackgroundMiyamoto, H., Yeh, S., Wilding, G., & Chang, C. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7379 · Cited by 203
Li, Y., Hwang, T. H., Oseth, L. A., Hauge, A., Vessella, R. L., Schmechel, S. C., Hirsch, B., Beckman, K. B., Silverstein, K. A., & Dehm, S. M. (2012) · Oncogene · doi:10.1038/onc.2011.637 · Cited by 202
Role of SRC-1 in the Promotion of Prostate Cancer Cell Growth and Tumor Progression
Agoulnik, I. U., Vaid, A., Bingman, W. E., Erdeme, H., Frolov, A., Smith, C. L., Ayala, G., Ittmann, M. M., & Weigel, N. L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3541 · Cited by 202
Self-citationMemarzadeh, S., Xin, L., Mulholland, D. J., Mansukhani, A., Wu, H., Teitell, M. A., & Witte, O. N. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.11.002 · Cited by 201
Donjacour, A. A. (1993) · Endocrinology · doi:10.1210/en.132.6.2342 · Cited by 200
Li, Y., Alsagabi, M., Fan, D., Bova, G. S., Tewfik, A. H., & Dehm, S. M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1998 · Cited by 199
Mitsiades, N., Sung, C. C., Schultz, N., Danila, D. C., He, B., Eedunuri, V. K., Fleisher, M., Sander, C., Sawyers, C. L., & Scher, H. I. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1335 · Cited by 197
Inhibition of the Androgen Receptor as a Novel Mechanism of Taxol Chemotherapy in Prostate Cancer
Gan, L., Chen, S., Wang, Y., Watahiki, A., Bohrer, L., Sun, Z., Wang, Y., & Huang, H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1504 · Cited by 197
Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer
Gnanapragasam, V. J., Leung, H. Y., Pulimood, A. S., Neal, D. E., & Robson, C. N. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2179 · Cited by 189
p300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6.
Debes, J. D., Schmidt, L. J., Huang, H., & Tindall, D. J. (2002) · PubMed · Cited by 189
Androgen action and metabolism in prostate cancer
Green, S. M., Mostaghel, E. A., & Nelson, P. S. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.09.046 · Cited by 181
Yoshida, T., Kinoshita, H., Segawa, T., Nakamura, E., Inoue, T., Shimizu, Y., Kamoto, T., & Ogawa, O. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0817 · Cited by 178
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial
Kibel, A. S. (2008) · Yearbook of Urology · doi:10.1016/s0084-4071(08)79094-8 · Cited by 178
Molecular Mechanisms of Androgen Action
Lindzey, J. K., Kumar, M. V., Grossman, M., Young, C. Y. F., & Tindall, D. J. (1994) · Vitamins and hormones · doi:10.1016/s0083-6729(08)61151-6 · Cited by 176
COUP-TFII inhibits TGF-β-induced growth barrier to promote prostate tumorigenesis
Qin, J., Wu, S.-P., Creighton, C. J., Dai, F., Xie, X., Cheng, C.-M., Frolov, A., Ayala, G., Lin, X., Feng, X.-H., et al. (2013) · Nature · doi:10.1038/nature11674 · Cited by 175
Gao, J., Arnold, J. T., & Isaacs, J. T. (2001) · PubMed · Cited by 175
Pleiotropic Biological Activities of Alternatively Spliced TMPRSS2/ERG Fusion Gene Transcripts
Wang, J., Cai, Y., Yu, W., Ren, C., Spencer, D. M., & Ittmann, M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1147 · Cited by 173
Li, C., Ao, J., Fu, J., Lee, D.-F., Xu, J., Lonard, D., & O'Malley, B. W. (2011) · Oncogene · doi:10.1038/onc.2011.151 · Cited by 173
Tu, J. J., Rohan, S., Kao, J., Kitabayashi, N., Mathew, S., & Chen, Y.-T. (2007) · Modern Pathology · doi:10.1038/modpathol.3800903 · Cited by 170
Hsp90: A Novel Target for Cancer Therapy
Solit, D., & Rosen, N. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802606777812068 · Cited by 170
Leon, C. G., Locke, J. A., Adomat, H. H., Etinger, S. L., Twiddy, A. L., Neumann, R. D., Nelson, C. C., Guns, E. S., & Wasan, K. M. (2010) · The Prostate · doi:10.1002/pros.21072 · Cited by 168
Park, J.-I., Lee, M.-G., Cho, K., Park, B.-J., Chae, K.-S., Byun, D.-S., Ryu, B.-K., Park, Y.-K., & Chi, S.-G. (2003) · Oncogene · doi:10.1038/sj.onc.1206478 · Cited by 168
Agoulnik, I. U., Vaid, A., Nakka, M., Alvarado, M., Bingman, W. E., Erdem, H., Frolov, A., Smith, C. L., Ayala, G. E., Ittmann, M. M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1023 · Cited by 168
Self-citationAndrogen receptor signaling and mutations in prostate cancer
Koochekpour, S. (2010) · Asian Journal of Andrology · doi:10.1038/aja.2010.89 · Cited by 168
A and B forms of the androgen receptor are present inhuman genital skin fibroblasts.
Wilson, C. M., & McPhaul, M. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.4.1234 · Cited by 164
Boddy, J. L., Fox, S. B., Han, C., Campo, L., Turley, H., Kanga, S., Malone, P. R., & Harris, A. L. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0460 · Cited by 162
Miller, D. C., Hafez, K. S., Stewart, A., Montie, J. E., & Wei, J. T. (2003) · Cancer · doi:10.1002/cncr.11635 · Cited by 161
Steketee, K., Timmerman, L., der Made, A. C. J. Z.-V., Doesburg, P., Brinkmann, A. O., & Trapman, J. (2002) · International Journal of Cancer · doi:10.1002/ijc.10495 · Cited by 159
Androgen receptor action in hormone‐dependent and recurrent prostate cancer
Agoulnik, I. U., & Weigel, N. L. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20811 · Cited by 156
Self-citationSrc Family Kinase Activity Is Up-Regulated in Hormone-Refractory Prostate Cancer
Tatarov, O., Mitchell, T. J., Seywright, M. M., Leung, H. Y., Brunton, V. G., & Edwards, J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1857 · Cited by 153
Decreased Expression and Androgen Regulation of the Tumor Suppressor Gene INPP4B in Prostate Cancer
Hodgson, M. C., Shao, L.-J., Frolov, A., Li, R., Peterson, L. E., Ayala, G., Ittmann, M., Weigel, N. L., & Agoulnik, I. U. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2314 · Cited by 152
Self-citationTargeting the stromal androgen receptor in primary prostate tumors at earlier stages
Niu, Y., Altuwaijri, S., Yeh, S., Lai, K., Yu, S., Chuang, K., Huang, S., Lardy, H. A., & Chang, C. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804701105 · Cited by 149
ETS transcription factors in endocrine systems
Gutierrez‐Hartmann, A., Duval, D. L., & Bradford, A. P. (2007) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2007.03.002 · Cited by 148
Guo, Y., Jacobs, S. C., & Kyprianou, N. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970516)71:4<573::aid-ijc11>3.0.co;2-d · Cited by 138
Thompson, J. S., Saatcioglu, F., Jänne, O. A., & Palvimo, J. J. (2001) · Molecular Endocrinology · doi:10.1210/mend.15.6.0647 · Cited by 135
Laverdière, J., Nabid, A., de Bedoya, L. D., Ébacher, A., Fortin, A., Wang, C. S., & HAREL, F. (2004) · The Journal of Urology · doi:10.1097/01.ju.0000112979.97941.7f · Cited by 130
Evidence for Calpain-Mediated Androgen Receptor Cleavage as a Mechanism for Androgen Independence
Libertini, S. J., Tepper, C. G., Rodriguez, V., Asmuth, D. M., Kung, H.-J., & Mudryj, M. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1072 · Cited by 129
Homozygous Deletions and Recurrent Amplifications Implicate New Genes Involved in Prostate Cancer
Liu, W., Xie, C., Zhu, Y., Li, T., Sun, J., Cheng, Y., Ewing, C. M., Dalrymple, S. L., Turner, A. R., Sun, J., et al. (2008) · Neoplasia · doi:10.1593/neo.08428 · Cited by 128
Ai, J., Wang, Y., Dar, J. A., Liu, J., Liu, L., Nelson, J. B., & Wang, Z. (2009) · Molecular Endocrinology · doi:10.1210/me.2009-0188 · Cited by 126 · cited 3×
“In addition to AR antagonists and approaches to further reduce levels of androgens, chaperone protein inhibitors (Hsp90), and histone deacetylase (HDAC) inhibitors to combat the reactivation of AR signaling that occurs in CRPC are being developed (Scher & Sawyers, 2005; Minucci & Pelicci, 2006; Rokhlin et al., 2006; A…”
BackgroundHobisch, A., Ramoner, R. E., Fuchs, D., Godoy‐Tundidor, S., Bartsch, G. H., Klocker, H., & Čulig, Z. (2001) · PubMed · Cited by 126
The role of antiandrogen monotherapy in the treatment of prostate cancer
Anderson, J. (2003) · British Journal of Urology · doi:10.1046/j.1464-410x.2003.04026.x · Cited by 124
Androgen receptor - an update of mechanisms of action in prostate cancer
Čulig, Z., Hobisch, A., Bartsch, G. C., & Klocker, H. (2000) · Urological Research · doi:10.1007/s002400000111 · Cited by 124
Yamaoka, M., Hara, T., Hitaka, T., Kaku, T., Takeuchi, T., Takahashi, J., Asahi, S., Miki, H., Tasaka, A., & Kusaka, M. (2012) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2012.01.001 · Cited by 123
Homma, Y., Kawabe, K., Tsukamoto, T., Yamanaka, H., Okada, K., Okajima, E., Yoshida, O., Kumazawa, J., Fang‐Liu, G., Lee, C., et al. (1997) · International Journal of Urology · doi:10.1111/j.1442-2042.1997.tb00138.x · Cited by 121
Bauman, D. R., Steckelbroeck, S., Williams, M. V., Peehl, D. M., & Penning, T. M. (2006) · Molecular Endocrinology · doi:10.1210/me.2005-0287 · Cited by 120
Antiandrogens in the Treatment of Prostate Cancer
Wirth, M. P., Hakenberg, O. W., & Froehner, M. (2006) · European Urology · doi:10.1016/j.eururo.2006.08.043 · Cited by 120
Kraus, S., Gioeli, D., Vomastek, T., Gordon, V., & Weber, M. J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0596 · Cited by 118
Yang, X., Guo, Z., Sun, F., Li, W., Alfano, A., Shimelis, H., Chen, M., Brodie, A. M. H., Chen, H., Xiao, Z., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.265124 · Cited by 118
Yan, J., Erdem, H., Li, R., Cai, Y., Ayala, G., Ittmann, M., Yu‐Lee, L., Tsai, S. Y., & Tsai, M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0955 · Cited by 117
Androgen Deprivation Increases p300 Expression in Prostate Cancer Cells
Heemers, H. V., Sebo, T. J., Debes, J. D., Regan, K. M., Raclaw, K. A., Murphy, L. M., Hobisch, A., Čulig, Z., & Tindall, D. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2836 · Cited by 111
Ianculescu, I., Wu, D., Siegmund, K. D., & Stallcup, M. R. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.300194 · Cited by 110
Duff, J. M., & McEwan, I. J. (2005) · Molecular Endocrinology · doi:10.1210/me.2005-0231 · Cited by 103
Schröder, F. H., Kurth, K., Fosså, S. D., Hoekstra, W. J., Karthaus, P., Debois, M., & Collette, L. (2004) · The Journal of Urology · doi:10.1097/01.ju.0000135742.13171.d2 · Cited by 100
Migliaccio, A., Varricchio, L., de Falco, A., Castoria, G., Arra, C., Yamaguchi, H., Ciociola, A., Lombardi, M., Stasio, R. D., Barbieri, A., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210487 · Cited by 98
Sen, A., O’Malley, K. J., Wang, Z., Raj, G. V., DeFranco, D. B., & Hammes, S. R. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.134064 · Cited by 91
Coactivators and nuclear receptor transactivation
Wolf, I. M., Heitzer, M. D., Grubisha, M. J., & DeFranco, D. B. (2008) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21755 · Cited by 90
Lai, K., Yamashita, S., Huang, C., Yeh, S., & Chang, C. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201101140 · Cited by 86
Novel Molecular Targets for the Therapy of Castration-Resistant Prostate Cancer
Agarwal, N., Sonpavde, G., & Sternberg, C. N. (2011) · European Urology · doi:10.1016/j.eururo.2011.12.028 · Cited by 82
Zietman, A. L., Nakfoor, B. M., Ea, P., & Le, G. (1997) · PubMed · Cited by 75
Palmberg, C., Koivisto, P., Hyylinen, E., Isola, J., Visakorpi, T., Kallioniemi, O., & Tammela, T. L. J. (1997) · European Urology · doi:10.1159/000474453 · Cited by 74
Hay, C. W., & McEwan, I. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032514 · Cited by 74
Yang, J. C., Ok, J.-H., Busby, J. E., Borowsky, A. D., Kung, H.-J., & Evans, C. P. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-0442 · Cited by 70
Transit of hormonal and EGF receptor-dependent signals through cholesterol-rich membranes
Freeman, M. R., Cinar, B., Kim, J., Mukhopadhyay, N. K., Vizio, D. D., Adam, R. M., & Solomon, K. R. (2006) · Steroids · doi:10.1016/j.steroids.2006.11.012 · Cited by 68
Chung, A. C., Zhou, S., Liao, L., Tien, J. C.-Y., Greenberg, N. M., & Xu, J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3168 · Cited by 67
Zietman, A. L., Prince, E. A., Nakfoor, B. M., & Shipley, W. U. (1997) · Urology · doi:10.1016/s0090-4295(97)00173-8 · Cited by 67
van de Wijngaart, D. J., Molier, M., Lusher, S. J., Hersmus, R., Jenster, G. W., Trapman, J., & Dubbink, H. J. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.039958 · Cited by 66
Rokhlin, O. W., Glover, R. B., Guseva, N. V., Taghiyev, A. F., Kohlgraf, K. G., & Cohen, M. B. (2006) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-05-0085 · Cited by 66
Coactivator selective regulation of androgen receptor activity
Agoulnik, I. U., & Weigel, N. L. (2009) · Steroids · doi:10.1016/j.steroids.2009.02.007 · Cited by 64
Self-citationHe, S., Zhang, C., Shafi, A. A., Sequeira, M., Acquaviva, J., Friedland, J. C., Sang, J., Smith, D. L., Weigel, N. L., Wada, Y., et al. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1698 · Cited by 64
Self-citationAndrogen Receptor Coactivators and Prostate Cancer
Agoulnik, I. U., & Weigel, N. L. (2008) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-69080-3_23 · Cited by 58
Self-citationEffect of sequencing of androgen deprivation and radiotherapy on prostate cancer growth
Kaminski, J., Hanlon, A. L., Joon, D. L., Meistrich, M. L., Hachem, P., & Pollack, A. S. (2003) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(03)00539-x · Cited by 57
Abiraterone and Novel Antiandrogens: Overcoming Castration Resistance in Prostate Cancer
Ferraldeschi, R., Pezaro, C. J., Karavasilis, V., & Bono, J. S. D. (2012) · Annual Review of Medicine · doi:10.1146/annurev-med-121211-091605 · Cited by 57
Léotoing, L., Manin, M., Monté, D., Baron, S., Communal, Y., Lours-Calet, C., VEYSSIERE, G., Morel, L., & Beaudoin, C. (2007) · Journal of Molecular Endocrinology · doi:10.1677/jme-07-0021 · Cited by 57
Cited by
The role of vitamin D in reducing cancer risk and progression
Feldman, D., Krishnan, A. V., Swami, S., Giovannucci, E., & Feldman, B. J. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3691 · Cited by 1,311
Mechanisms of resistance in castration-resistant prostate cancer (CRPC).
Chandrasekar, T., Yang, J. C., Gao, A. C., & Evans, C. P. (2015) · PubMed · doi:10.3978/j.issn.2223-4683.2015.05.02 · Cited by 514
Role of Androgen Receptor in Prostate Cancer: A Review
Fujita, K., & Nonomura, N. (2019) · The World Journal of Men's Health · doi:10.5534/wjmh.180040 · Cited by 483
Barnard, M., Quanson, J. L., Mostaghel, E., Pretorius, E., Snoep, J. L., & Storbeck, K.-H. (2018) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2018.06.013 · Cited by 72
Morell, C., Bort, A., Vara-Ciruelos, D., Ramos-Torres, Á., Altamirano-Dimas, M., Díaz-Laviada, I., & Rodríguez-Henche, N. (2016) · PLOS ONE · doi:10.1371/journal.pone.0162977 · Cited by 50
Metadata
- Authors
- Shafi, A. A., Yen, A. E., & Weigel, N. L.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2013-12
- Volume
- 140
- Issue
- 3
- Pages
- 223-238
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W2036274810
- Cited by
- 420
- References
- 216
- FWCI
- 19.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.